Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of 3% LTX-109 Hydrogel for Nasal Decolonisation of Staphylococcus aureus
2022-001938-11Phase 2Completed
- Sponsor
- Pharma Holdings AS
- Start
- Jun 2022
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus nasal carriage comparing LTX-109 3% hydrogel with Placebo hydrogel (2 arms). Primary endpoint: Primary bacterial eradication during operation window. Started Jun 2022; status: completed.
02
Drugs
voxvoganan
03
Conditions
Staphylococcus aureus nasal carriage
Beyond the preview
Go deeper on 2022-001938-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001938-11.